Spanish private equity firm Buenavista Equity Partners, which specialises in investments in the lower- and mid-market segments, has unveiled a new healthcare-focused fund, BV Healthcare Growth Innvierte I, with an initial closing of €100m.
The fund, which will look to invest in startups and scaling businesses, has plans to increase commitments up to a hard cap of €150m.
This initiative is a joint effort between Buenavista and Columbus Venture Partners, a specialist in biotech venture investments. Together, the two firms bring experience from 45 prior investments in the healthcare sector.
A key contributor to the fund is Spain’s Centre for Technological Development and Innovation (CDTI), which has committed up to €58m through its Innvierte Programme. This co-investment initiative focuses on fostering groundbreaking therapies and drug development within Spain.
The fund will target healthcare startups with low scientific or technological risk and those nearing commercialisation. Investments will concentrate on areas such as: biotechnology and pharmaceuticals; precision medicine; diagnostics and digital therapies; AI and big data in healthcare; contract research and manufacturing organisations (CROs and CDMOs); and scaling of industrial healthcare production.
Individual investments will range up to €15m, with plans to build a portfolio of 10–12 companies, predominantly in Spain.
The fund’s inaugural investment is in Syngoi, a Contract Development and Manufacturing Organisation (CDMO) based in Zamudio, Bizkaia. Syngoi specialises in synthetic DNA for advanced therapies, including mRNA vaccines and gene therapies.
